Passive Avoidance in Adult and Middle-Aged Male C57BL/6 Mice after Intranasal α-Synuclein Administration
https://doi.org/10.33647/2074-5982-21-4-143-147
Abstract
A comparative study of the effects of α-synuclein species (monomers, oligomers or fibrils alone or in combination) administered intranasally for 14 days on passive avoidance in adult (3–7 months) and middle-aged (10–13 months) male C57BL/6 mice was conducted. Middle-aged mice treated with a solution of α-synuclein fibrils and oligomers were found to have a reduced latency to entry in the dark compartment during acquisition phase compared to controls (р<0.05). None of the experimental groups showed any impairment in long-term memory 24 h after training. The data obtained can be used in modeling human neurodegenerative diseases in animals.
About the Authors
O. A. SolovievaRussian Federation
Olga A. Solovieva
125315, Moscow, Baltiyskaya Str., 8
N. P. Mikhaylova
Russian Federation
Nataliya P. Mikhaylova
125315, Moscow, Baltiyskaya Str., 8
M. A. Gruden
Russian Federation
Marina А. Gruden, Cand. Sci. (Chem.)
125315, Moscow, Baltiyskaya Str., 8
V. V. Sherstnev
Russian Federation
Vladimir V. Sherstnev, Dr. Sci. (Med.), Prof.
125315, Moscow, Baltiyskaya Str., 8
Z. I. Storozheva
Russian Federation
Zinaida I. Storozheva, Dr. Sci. (Biol.)
125315, Moscow, Baltiyskaya Str., 8
References
1. Solovieva O.A., Gruden M.A., Kalinin I.A., Ratmirov A.M., Sherstnev V.V. Vliyanie kompozicionnoj smesi nativnoj i oligomernoj form belka α-sinukleina pri intranazal'nom vvedenii na povedenie stareyushchih myshej [Effect of a composite mixture of native and oligomeric forms of the α-synuclein protein upon intranasal administration on aging mouse behavior]. Pathogenesis. 2018;16(4):51–57. (In Russian)]. DOI: 10.25557/2310-0435.2018.04.51-57.
2. Alwani A., Maziarz K., Burda G., Jankowska-Kiełtyka M., Roman A., Łyszczarz G., Er S., Barut J., Barczyk-Woźnicka O., Pyza E., Kreiner G., Nalepa I., Chmielarz P. Investigating the potential effects of α-synuclein aggregation on susceptibility to chronic stress in a mouse Parkinson's disease model. Pharmacological Reports. 2023;75(6):1474–1487. DOI: 10.1007/s43440-023-00530-z.
3. Carta A.R., Boi L., Pisanu A., Palmas M.F., Carboni E., De Simone A. Advances in modelling alpha-synuclein-induced Parkinson’s diseases in rodents: Virus-based models versus inoculation of exogenous preformed toxic species. J. of Neuroscience Methods. 2020;338:108685. DOI: 10.1016/j.jneumeth.2020.108685.
4. Gruden M.A., Davidova T.V., Yanamandra K., Kucheryanu V.G., Morozova-Roche L.A., Sherstnev V.V., Sewell R.D. Nasal inoculation with α-synuclein aggregates evokes rigidity, locomotor deficits and immunity to such misfolded species as well as dopamine. Behavioural Brain Research. 2013;15(243):205–212. DOI: 10.1016/j.bbr.2013.01.011.
5. Hasegawa M., Nonaka T., Masuda-Suzukake M. α-Synuclein: experimental pathology. Cold Spring Harbor Perspectives in Medicine. 2016;6(9):a024273. DOI: 10.1101/cshperspect.a024273.
6. Lai T.T., Gericke B., Feja M., Conoscenti M., Zelikowsky M., Richter F. Anxiety in synucleinopathies: neuronal circuitry, underlying pathomechanisms and current therapeutic strategies. NPJ Parkinsons Disease. 2023:22;9(1):97. DOI: 10.1038/s41531-023-00547-4.
Review
For citations:
Solovieva O.A., Mikhaylova N.P., Gruden M.A., Sherstnev V.V., Storozheva Z.I. Passive Avoidance in Adult and Middle-Aged Male C57BL/6 Mice after Intranasal α-Synuclein Administration. Journal Biomed. 2025;21(4):143-147. (In Russ.) https://doi.org/10.33647/2074-5982-21-4-143-147



























